Meet a Researcher: Dr Rachel Taylor
Dr Rachel Taylor is part of the UK Inherited Retinal Dystrophy Consortium (UKIRDC) team at the University of Manchester.
Search
Search results
Genetic testing: an essential topic for discussion with the IRD community
As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.
Meet a Researcher: Hajrah Sarkar
Hajrah Sarkar is a PhD student whose project is funded by Retina UK.
Significantly worse vision found in female carriers of X-linked RP and Choroideremia
It was previously believed that female carriers of X-linked inherited retinal diseases (IRDs) like X-linked retinitis pigmentosa (RP and Choroideremia) remained unaffected by sight loss.
Exciting developments for new treatment research
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
Applying for research funding
We provide funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease.
Meet our Trustee: Simon Keightley
Simon spent 40 years as a consultant ophthalmic surgeon at the North Hampshire Hospital in Basingstoke.
Applications invited for project grants and studentships
Retina UK invites applications for funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease. We are particularly keen to receive proposals with demonstrable translational potential.
Look Forward – Summer 2025 – Issue 186
This edition marks the start of the charity's 50th anniversary year. It includes lots of ways to get involved over the next 12 months along with details of our Annual and Professionals' Conferences in September.
PDE6A gene therapy trial report: the importance of scientific learnings in an unsuccessful trial
Researchers from the University Hospital Tübingen in Germany recently announced that there were no signs of visual gains in an early-phase clinical trial of a PDE6A gene therapy for Retinitis Pigmentosa (RP).